Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics宣佈了支持GT-02287在GBA-1和特發性帕金森病的臨床動物模型中病變修正活性的新證據的展示。
In animal models of GBA-1 and idiopathic Parkinson's disease, rescue of motor and cognitive function associated with administration of GT-02287 was observed to be persistent upon wash out of GT-02287 without significant effect in performance for more than a week following discontinuation when compared to the animals in which treatment was continued.
在GBA-1和特發性帕金森病的動物模型中,發現Gt-02287給藥後與運用Gt-02287時持續的對動力和認知功能的挽救在Gt-02287停藥後依然持久,與繼續治療的動物相比,停藥超過一週後的表現沒有明顯影響。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。